{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:veristat-q131986594-answer-518eadbfcb69743d223e","key":"buyer_question:veristat-q131986594-answer-518eadbfcb69743d223e","kind":"buyer_question","slug":"veristat-q131986594-answer-518eadbfcb69743d223e","canonicalUrl":"https://readyscan.ai/corpus/buyer-question/veristat-q131986594-answer-518eadbfcb69743d223e","machineUrl":"https://readyscan.ai/discovery/corpus/buyer-question/veristat-q131986594-answer-518eadbfcb69743d223e.json","datePublished":"2026-10-25","dateModified":"2026-10-25","materialFingerprint":"fnv1a64:d1e4b547ec733021","membershipFingerprint":"fnv1a64:85a7c038071c850f","relatedEntitySlugs":["veristat-q131986594"],"relatedSurfaceKeys":["buyer_question:veristat-q131986594-answer-1a02751483e69f2ab788","buyer_question:veristat-q131986594-answer-3412882f879455f677e8","buyer_question:veristat-q131986594-answer-34458a603e1bff48200e","buyer_question:veristat-q131986594-answer-39b32ed129c8622469be","buyer_question:veristat-q131986594-answer-5fbc154d4b1ba432fb13","buyer_question:veristat-q131986594-answer-6212fedf973f6b93dd9b","buyer_question:veristat-q131986594-answer-68df9892211ef7060c6a","buyer_question:veristat-q131986594-answer-aa510bdb0ccf031ed5bb","buyer_question:veristat-q131986594-answer-c4405cf9ec71555384b3","buyer_question:veristat-q131986594-answer-cfd6628316e7e985c4b7","buyer_question:veristat-q131986594-answer-fe587a9c2de404de4138","evidence:veristat-q131986594"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"veristat-q131986594-content-20eafb8411341c3d-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q131986594","sourceRevisionId":"Q131986594:content:b79eadc27cef7bcc","sourceContentHash":"fnv1a64:1dce5caf659418af","recordRevisionId":"Q131986594:content:b79eadc27cef7bcc","recordContentHash":"fnv1a64:b2a53c98a2b6b9ea","sourceCanonicalUrl":"https://www.veristat.com/","sourceModifiedAt":"2026-10-25T07:29:48.087Z","observedOn":"2026-10-25","permission":{"basis":"public_information","evidenceUrl":"https://www.veristat.com/"},"attributionUrl":"https://www.veristat.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"How does Veristat's medical affairs team support patient safety throughout a trial?","summary":"Cited source answers across 1 active corpus record.","question":"How does Veristat's medical affairs team support patient safety throughout a trial?","answers":[{"entitySlug":"veristat-q131986594","entityName":"Veristat","answer":"“Veristat's MDs stay directly connected to patients from trial start to finish, collaborating across clinical operations, biometrics, and medical writing to ensure safety considerations are built into decisions throughout the program, not just addressed after issues arise.”","sourceUrls":["https://www.veristat.com/medical-affairs-and-patient-safety-expertise"]}]}